Baker Bros bags $340m from BeiGene block

biopharma_stocks_adobe_575x375.jpg
By Rashmi Kumar
02 Dec 2020

Baker Bros Advisors, a shareholder in Chinese biopharmaceutical company BeiGene, has raised $340.1m from a sell-down of the firm’s American depositary shares.

The vendor has offloaded approximately 1.5m ADS in the block trade at $225 each. It could sell an additional 151,154 ADS in a greenshoe option that can be exercised within 30 days.

Goldman Sachs was the sole underwriter on the Nasdaq-listed stock’s sell-down.

BeiGene’s shares had ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial